As part of finished pharmaceutical forms of medicinal products, they are used to cure, diagnose or prevent a disease, to change the condition, structures or physiological functions of the body, to care, treat and mitigate symptoms; excipient is any substance of a dosage form other than API or finished pharmaceutical product and, accordingly, does not exert a pharmacological, immunological or diagnostic action, is included as a compound in the medicinal product and is required for its production (manufacture), storage and/or use; narcotic medicinal products are medicinal products classified as narcotic in accordance with the legislation; poisonous medicinal products are medicinal products classified as poisonous by the central executive authority in charge of shaping the state policy in the field of health care; highly potent medicinal products are medicinal products classified as highly potent by the central executive authority in charge of shaping the state policy in the field of healthcare; radioactive medicinal products are medicinal products used in medical practice due to their properties to produce ionizing radiation; State Register of Medicinal Products of Ukraine is a regulatory document containing information on medicinal products approved for manufacture and use in medical practice; pharmacopoeial monograph is a regulatory technical document specifying the requirements for a medicinal product, its packaging, storage conditions, expiry date, and methods of quality control for medicinal products; technological regulations for manufacturing a medicinal product (technological regulations) are the regulatory documents specifying the manufacturing methods, technical means, norms and regulatory standards for medicinal product manufacturing; State Pharmacopoeia of Ukraine is a regulatory document including the general requirements for medicinal products, pharmacopoeial monographs, as well as quality control methods for medicinal products; quality of a medicinal product is a set of features due to which the medicinal product can satisfy consumers according to its intended purpose and comply with the requirements established by the legislation; expiry date of medicinal products is a period of time within which the medicinal product retains its quality, provided that it is stored in compliance with the requirements of regulatory technical documentation; dosage form is a form combination in which the medicinal product is presented by the manufacturer (a form of presentation), as well as the form in which the medicinal product is intended to be used, including its physical configuration (a form of administration); “in bulk” product is any medicinal product intended for manufacturing a finished pharmaceutical product, which has completed all processing stages, except for the pre-packaging and/or final packaging and labelling. The application for state registration of a medicinal product (except for API and medicinal products, subject to procurement based on the results of a procurement procedure conducted by a specialised procurement organisation for implementation of a procurement agreement between the Ukrainian central executive authority in charge of shaping and implementing the state policy in the field of healthcare and the relevant specialised procurement organisation), in addition to the documents specified in part four of this Article, shall be accompanied by a certified copy of a document confirming the compliance of the manufacturing conditions of a medicinal product submitted for registration with the medicinal product manufacturing requirements in Ukraine, issued by the central executive authority implementing the state policy in the field of control over the quality and safety of medicinal products, according to procedure established by the central executive authority in charge of shaping the state policy in the field of healthcare. The state registration of a medicinal product, purchased by an individual authorised to procure in the field of healthcare and at the same time registered by the competent authority of the United States of America, the Swiss Confederation, Japan, Australia, Canada and used on the territory of these countries or by the competent authority of the European Union under the centralised procedure and used on the territory of the European Union Member States, shall be carried out with the following peculiarities (without restrictions on the possibility of state registration under the procedure specified in part five of this Article): an application for the state registration of such a medicinal product shall be accompanied by a document confirming the registration of the medicinal product in the relevant country or registration by the competent authority of the European Union under a centralised procedure and use on the territory of the European Union Member States as of the date of submission of the state registration application, signed by the applicant or their authorised representative; registration dossier materials; methods of quality control of the finished medicinal product (final product); a report on evaluation of this medicinal product by the regulatory authority of the country where the medicinal product is registered; an instruction for medical use of the medicinal product in the original language (in a language other than the state one); a summary of product characteristics in the original language (in a language other than the state one); a graphic image of the medicinal product package design and label text of the primary and secondary (if any) packages; translations of the label text of primary and secondary (if any) packages of the medicinal product and instruction for medical use, summary of product characteristics in the state language according to the structure and under the procedure determined by the central executive authority in charge of shaping and implementing the state policy in the field of healthcare signed by the applicant or his authorised representative; a certified copy of the document confirming the compliance of conditions for the manufacture of the medicinal product submitted for registration with the medicinal product manufacturing requirements in Ukraine, issued by the central executive authority implementing the state policy in the field of control over the quality and safety of medicinal products, according to the procedure established by the central executive authority in charge of shaping and implementing the state policy in the field of healthcare, or a written obligation of the manufacturer to produce the relevant medicinal product for delivery to Ukraine at the same manufacturing sites used in the manufacturing of medicinal products intended to be used in the respective country of registration (the United States of America, the Swiss Confederation, Japan, Australia, Canada or the European Union Member States); the period of authenticity verification of the registration materials for the relevant medicinal product shall not exceed seven working days from the date of submission of these materials. The state registration of a medicinal product purchased by an individual authorised to make procurements in the field of healthcare, regardless of the manufacturer's country, shall be conducted with the following peculiarities: at the applicant's request, the state registration of such a medicinal product may be conducted with labelling and instruction for medical use of the medicinal product that meet the requirements of parts one, two, three and five of Article 12 of this Law, or with labelling, instruction for medical use of the medicinal product and summary of product characteristics in the original language (in a language other than the state one); if the state registration of a medicinal product is conducted with labelling and instruction for medical use of the medicinal product that meet the requirements of parts one, two, three and five of Article 12 of this Law, the application for state registration of such a medicinal product shall be accompanied by registration dossier materials; materials on methods of the medicinal product quality control; a document confirming the payment of registration fee; labelling of primary and secondary (if any) packages of the medicinal product; instruction for medical use of the medicinal product; a certified copy of the document confirming the compliance of manufacturing conditions of the medicinal product submitted for registration with the medicinal product manufacturing requirements in Ukraine, issued by the central executive authority implementing the state policy in the field of control over the quality and safety of medicinal products, according to the procedure established by the central executive authority in charge of shaping and implementing the state policy in the field of healthcare; if the state registration of a medicinal product is conducted with labelling, instruction for medical use of the medicinal product and summary of product characteristics in the original language (in a language other than the state one), the application for state registration of such a medicinal product shall be accompanied by materials of registration dossier; materials on methods of the medicinal product quality control; a document confirming the payment of registration fee; a graphic image of the medicinal product package design; a sample of the original instruction for medical use of the medicinal product and summary of product characteristics; translations of the label text of primary and secondary (if any) packages of the medicinal product, instruction for medical use of the medicinal product and summary of product characteristics in the state language according to the structure and under the procedure determined by the central executive authority in charge of shaping and implementing the state policy in the field of healthcare, signed by the applicant or his authorised representative; a certified copy of the document confirming the compliance of manufacturing conditions of the medicinal product submitted for registration with the medicinal product manufacturing requirements in Ukraine, issued by the central executive authority implementing the state policy in the field of control over the quality and safety of medicinal products, according to the procedure established by the central executive authority in charge of shaping and implementing the state policy in the field of healthcare; the period of an expert evaluation of the registration materials shall not exceed 30 working days. In connection with spreading the coronavirus disease (COVID-19) pandemic to ensure the possibility of emergency medical use of vaccines or other medical immunobiological preparations for the specific prevention of coronavirus disease (COVID-19) according to the procedure for state registration under the obligation established by the Cabinet of Ministers of Ukraine, such vaccines or others medical immunobiological preparations may be subject to accelerated state registration if the central executive authority in charge of shaping and implementing the state policy in the field of healthcare decides to approve the state registration of vaccines or other medical immunobiological preparations for emergency medical use, taking into account certain obligations, if the applicant can prove the absence of the possibility to provide full data on the efficacy and safety of vaccines or other medical immunobiological preparations under the normal conditions of use for objective reasons and if: 1) the available data on the successful preclinical studies/trials, separate phases of clinical trials/studies and the obtained results together contain scientifically substantiated evidence, including data from adequate and well-controlled studies, that suggests that vaccines or other medical immunobiological preparations may be effective for the coronavirus disease (COVID-19) prevention; 2) an emergency use authorisation is granted by the competent authority of the United States of America, the United Kingdom, the Swiss Confederation, Japan, Australia, Canada, the People's Republic of China, India or under a centralised procedure by the competent authority of the European Union according to the national legislation of the country granting the authorisation or the European Union or vaccine or other medical immunobiological preparations is prequalified by the World Health Organization; 3) such a medicinal product is not developed in a state duly recognised as the aggressor state; 4) the known and potential benefits of vaccines or other medical immunobiological preparations, when used to prevent coronavirus disease (COVID-19), outweigh the known and potential risks of using such vaccines or other medical immunobiological preparations. If the competent authority of the United States of America, the United Kingdom, the Swiss Confederation, Japan, Australia, Canada, the People's Republic of China, India or under a centralised procedure the competent authority of the European Union, according to the national legislation of the country granting the authorisation or the European Union, is granted the authorisation for the emergency use of a vaccine or other medical immunobiological preparation, or a vaccine or other medical immunobiological preparation is registered by such competent authority under a certain condition or is granted the WHO prequalification, such a vaccine or other medical immunobiological preparation may be provided with accelerated registration in Ukraine for emergency medical use under the procedure established by the Cabinet of Ministers of Ukraine, taking into account the following peculiarities: 1) an application for state registration for emergency medical use shall be accompanied solely by a document confirming the decision to grant an authorisation for emergency use or registration under a certain condition in the relevant country or registration under a certain condition by the competent authority of the European Union (or another essentially identical decision under the applicable laws of the United States of America, the United Kingdom, the Swiss Confederation, Japan, Australia, Canada, the People's Republic of China, India or under a centralised procedure by the competent authority of the European Union according to the national legislation of the country granting the authorisation or the European Union) on the date of submission of an application for state registration for emergency medical use, signed by the applicant or his authorised representative; a vaccine or other medical immunobiological preparation evaluation report drawn up by the regulatory authority of the country in which the vaccine or other medical immunobiological preparation is registered (if any, if such a document is provided for under the relevant country legislation, in the absence of such a document, a relevant note shall be made in the application for state registration for emergency medical use); a document on risk assessment and management approved by a decision on granting an authorisation for emergency use or on registration under a certain condition in the relevant country or registration under a certain condition by the competent authority of the European Union (if any, if such a document is provided for according to the relevant country legislation; in the absence of such a document, a corresponding note shall be made in the application for state registration for emergency medical use); an instruction for medical use in the original language (in a language other than the state one), a summary of product characteristics in the original language (in a language other than the state one) (if any, if such a document is provided for according to the relevant country legislation; in the absence of such a document, a corresponding note shall be made in the application for state registration for emergency medical use); a graphic image of the package design and label text(s) of the primary and secondary (if any) packages. The List of Business Entities Entitled to Conduct Electronic Retailing of Medicinal Products is maintained according to the procedure approved by the central executive authority in charge of shaping and implementing the state policy in the field of healthcare; the website of the business entity entitled to conduct electronic retailing of medicinal products shall contain information on the contact details of the licensing authority, the state authorities for control over the medicinal product quality; the logo with a hypertext link displayed on each website page and routed the consumer to the page of the List of Business Entities Entitled to Conduct Electronic Retailing of Medicinal Products (such a logo is used solely by the pharmacies included in the List of Business Entities Entitled to Conduct Electronic Retailing of Medicinal Products); an option of providing a pharmacist's consultation (if necessary) when ordering a medicinal product through the pharmacy's website; the delivery cost of a medicinal product.